Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
J-Y Blay,M von Mehren,R L Jones,J Martin-Broto,S Stacchiotti,S Bauer,H Gelderblom,D Orbach,N Hindi,A Dei Tos,M Nathenson,J.-Y. Blay,M. von Mehren,R.L. Jones,J. Martin-Broto,S. Stacchiotti,S. Bauer,H. Gelderblom,D. Orbach,N. Hindi,A. Dei Tos,M. Nathenson
DOI: https://doi.org/10.1016/j.esmoop.2023.101618
IF: 6.883
2023-08-26
ESMO Open
Abstract:Synovial sarcoma is a rare sarcoma with an incidence of 3/10e6/yr affecting all ages. Synovial sarcomas present with translocations affecting SS18 and SSX1, SSX2, SSX4 genes, whose protein products affects the transcriptional program of the cancer cell. Treatment of synovial sarcoma in localized phase follows the usual rules of sarcoma treatment, with uncertainties on the value of systemic treatment. In advanced phase, the disease is rarely curable, with current systemic treatments. Immunotherapy with autologous modified T cell recognizing MAGE-A4 or NY-ESO-1 have provided high response rates in recent reports. Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. Although it can occur at any age, it typically affects younger adults and children, with a peak incidence in the fourth decade of life. In >95% of cases, the oncogenic driver is a translocation between chromosomes X and 18 that leads to the formation of the SS18::SSX fusion oncogenes. Early and accurate diagnosis is often a challenge; optimal outcomes are achieved by referral to a specialist center for diagnosis and management by a multidisciplinary team as soon as SS is suspected. Surgery with or without radiotherapy and/or chemotherapy can be effective in localized disease, especially in children. However, the prognosis in the advanced stages is poor, with treatment strategies that have relied heavily on traditional cytotoxic chemotherapies. Therefore, there is an unmet need for novel effective management strategies for advanced disease. An improved understanding of disease pathology and its molecular basis has paved the way for novel targeted agents and immunotherapies that are being investigated in clinical trials. This review provides an overview of the epidemiology and characteristics of SS in children and adults, as well as the patient journey from diagnosis to treatment. Current and future management strategies, focusing particularly on the potential of immunotherapies to improve clinical outcomes, are also summarized.
oncology